impotence PILL APPROVED
Title: impotence PILL APPROVED , FDA Consumer, 03621332, Jul/Aug98, Vol. 32, Issue 4
Section: UPDATES
The first oral pill approved in the United States to treat impotence may help stimulate sexual response in many of the millions of American men affected by the condition.
Approved March 27, Viagra (sildenafil citrate) leads to an erection by increasing the blood flow to certain areas of the penis.
Viagra was studied in men with various conditions often associated with impotence , such as prostate problems, hypertension, and coronary artery disease, as well as in men with no identifiable physical cause. The studies indicated that men with diabetes or radical prostate surgery experienced less improvement than others.
Viagra is taken one hour before sexual activity and should be taken in the recommended dose, not more than once a day.
Viagra’s most common side effects include headache, flushing and indigestion. In some cases, men experienced vision changes, mostly in their color perception.
The drug is manufactured by Pfizer Pharmaceuticals, New York City. Viagra’s labeling and other information can be found on FDA’s Website at www.fda.gov/cder/news/viagra,htm
Men who are currently using medicines that contain nitrates, such as nitroglycerin, should not use Viagra because taken together the drugs can lower blood pressure too much. In addition, men who have medical conditions that may cause a sustained erection, such as sickle cell anemia, leukemia, or multiple myeloma, or who have an abnormally shaped penis may not be able to take Viagra.
Viagra has not been studied with other treatments for impotence , so use in combination with other treatments is not recommended.
Copyright of FDA Consumer is the property of Food & Drug Administration and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: FDA Consumer, Jul/Aug98, Vol. 32 Issue 4, p5, 1p
